MetaVia (Biotechnology) Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
MTVA
- Investments
-
2
- Share Price
-
$1.30
- (As of Friday Closing)
MetaVia (Biotechnology) General Information
Description
MetaVia Inc is a clinical-stage biotechnology company focused on developing treatments for liver-related cardiometabolic diseases. Its product pipeline includes DA-1726, an oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor agonist, being developed for metabolic and alcohol-associated liver diseases. The company is also developing vanoglipel (DA-1241), a GPR119 agonist, in combination with resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Contact Information
Website
www.metaviatx.comCorporate Office
- 545 Concord Avenue
- Suite 210
- Cambridge, MA 02138
- United States
Corporate Office
- 545 Concord Avenue
- Suite 210
- Cambridge, MA 02138
- United States
MetaVia (Biotechnology) Timeline
MetaVia (Biotechnology) Stock Performance
As of 13-Nov-2026, MetaVia (Biotechnology)’s stock price is $1.30. Its current market cap is $8.56M with 6.59M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.30 | $1.30 | $0.97 - $13.42 | $8.56M | 6.59M | 113K | -$2.78 |
MetaVia (Biotechnology) Financials Summary
As of 30-Sep-2026, MetaVia (Biotechnology) has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (2,114) | 5,245 | (4,025) | (7,685) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (15,986) | (13,464) | (28,492) | (12,925) |
| Net Income | (15,692) | (12,973) | (27,592) | (12,470) |
| Total Assets | 9,554 | 11,123 | 16,260 | 22,781 |
| Total Debt | 160 | 210 | 136 | 203 |
MetaVia (Biotechnology) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MetaVia (Biotechnology) Comparisons
Industry
Financing
Details
MetaVia (Biotechnology) Competitors (16)
One of MetaVia (Biotechnology)’s 16 competitors is Altimmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Immune Pharmaceuticals | Formerly VC-backed | Fort Lee, NJ | ||||
| Climb Bio | Formerly VC-backed | Wellesley Hills, MA | ||||
| CEL-SCI | Corporation | Vienna, VA | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA |
MetaVia (Biotechnology) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MetaVia (Biotechnology) Patents
MetaVia (Biotechnology) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022147499-A1 | Method of treating viral infections with a combination of niclosamide and gemcabene | Inactive | 04-Jan-2021 | ||
| US-20230248678-A1 | Gemcabene for treating inflammation | Pending | 24-Jun-2020 | ||
| EP-4171541-A1 | Gemcabene for treatment of cytokine storms and viral-induced inflammation | Inactive | 24-Jun-2020 | ||
| WO-2021262992-A1 | Gemcabene for treatment of cytokine storms and viral-induced inflammation | Inactive | 24-Jun-2020 | ||
| EP-4146172-A1 | Niclosamide formulations and methods of use | Inactive | 05-May-2020 | A61K9/2077 |
MetaVia (Biotechnology) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MetaVia (Biotechnology) Acquisitions (2)
MetaVia (Biotechnology)’s most recent deal was a Merger/Acquisition with ANA Therapeutics. The deal was made on 13-Jan-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ANA Therapeutics | 13-Jan-2021 | Merger/Acquisition | Drug Discovery | ||
| Gemphire Therapeutics | 30-Dec-2019 | Merger/Acquisition | Drug Discovery |
MetaVia (Biotechnology) ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
MetaVia (Biotechnology) FAQs
-
When was MetaVia (Biotechnology) founded?
MetaVia (Biotechnology) was founded in 2014.
-
Where is MetaVia (Biotechnology) headquartered?
MetaVia (Biotechnology) is headquartered in Cambridge, MA.
-
What is the size of MetaVia (Biotechnology)?
MetaVia (Biotechnology) has 8 total employees.
-
What industry is MetaVia (Biotechnology) in?
MetaVia (Biotechnology)’s primary industry is Drug Discovery.
-
Is MetaVia (Biotechnology) a private or public company?
MetaVia (Biotechnology) is a Public company.
-
What is MetaVia (Biotechnology)’s stock symbol?
The ticker symbol for MetaVia (Biotechnology) is MTVA.
-
What is the current stock price of MetaVia (Biotechnology)?
As of 13-Nov-2026 the stock price of MetaVia (Biotechnology) is $1.30.
-
What is the current market cap of MetaVia (Biotechnology)?
The current market capitalization of MetaVia (Biotechnology) is $8.56M.
-
Who are MetaVia (Biotechnology)’s competitors?
Altimmune, Immune Pharmaceuticals, Climb Bio, CEL-SCI, and Arcus Biosciences are some of the 16 competitors of MetaVia (Biotechnology).
-
What is MetaVia (Biotechnology)’s annual earnings per share (EPS)?
MetaVia (Biotechnology)’s EPS for 12 months was -$2.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
